 BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia CIN with revenues beginning in early 2022. On Monday morning 92021, BeyondSpring will present at ESMO late breaking Phase 3 trial data on Plinabulin to potentially extend survival for Non-Small Cell Lung Cancer NSCLC patients. 